MTOR and hepatocellular carcinoma: For example, telomerase could be a pivotal candidate drug target for the suppression of hypovascular early HCC development, while proteins associated with Wnt or PIK3CA-mTOR signaling can be targeted to inhibit the progression from hypovascular to hypervascular HCC.